Device Trial Radar · NCT05778851
Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Apr 12, 2023
Primary completion
Jul 31, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Lucid Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Medex15
- First posted
- Mar 21, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a prospective randomized, controlled, virtual, patient study to measure the impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral. The participants will complete two rounds of questions concerning the assessed risk for BE and decision for endoscopy referral of 6 patient cases (clinical vignettes). After the first round has been completed, an EsoCheck/EsoGuard educational information package and the second round of 6 clinical vignettes including EsoGuard results will be sent.
Conditions
- Barrett Esophagus
Interventions
EsoGuard resultDevice
Education slide-set EsoGuard and patient cases including EsoGuard result
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Impact of EsoCheck/EsoGuard on Provider's Decision for Upper Endoscopy ReferralTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lucid Diagnostics
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.